Nuvectis Pharma, Inc.(NVCT)

Biotechnology · Fort Lee, NJ

$20.62-0.77 (-3.60%)

Delayed quote: Oct 6, 2026, 12:10 PM EDT

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T16:13:21.054Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:13:21.054Z.

Quote observation: 2026-10-06T16:10:16.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 547,181,187
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 22,160,000
TTM operating income · period ending 2026-06-30: -28,868,000

FMP input reference: b447d722f006e82d19b5d98ef6acffd249f934693947ae19b5e437b2b2585766

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

NVCT EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

NVCT Competitors' EV/EBIT Ratio

NVCT

Nuvectis Pharma, Inc.

Current

Market Cap

$547.18M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACRS

Aclaris Therapeutics, Inc.

vs NVCT

Market Cap

$549.58M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BLSM

BlossomHill Therapeutics, Inc.

vs NVCT

Market Cap

$549.34M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MMEDV

MiniMed Group, Inc.

vs NVCT

Market Cap

$560.00M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CRMD

CorMedix Inc.

vs NVCT

Market Cap

$566.03M

EV/EBIT Ratio

2.09x

TTM Avg

6.25x

3Y Avg

15.98x

5Y Avg

15.98x

PHAT

Phathom Pharmaceuticals, Inc.

vs NVCT

Market Cap

$542.17M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DCTH

Delcath Systems, Inc.

vs NVCT

Market Cap

$539.40M

EV/EBIT Ratio

N/A

TTM Avg

189.50x

3Y Avg

189.50x

5Y Avg

189.50x

CTMX

CytomX Therapeutics, Inc.

vs NVCT

Market Cap

$567.12M

EV/EBIT Ratio

N/A

TTM Avg

14.25x

3Y Avg

18.01x

5Y Avg

18.01x

AQST

Aquestive Therapeutics, Inc.

vs NVCT

Market Cap

$572.76M

EV/EBIT Ratio

N/A

TTM Avg

78.65x

3Y Avg

78.65x

5Y Avg

78.65x

PROK

ProKidney Corp.

vs NVCT

Market Cap

$536.22M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Nuvectis Pharma, Inc. (NVCT)	$547.18M	N/A	N/A	N/A	N/A
Aclaris Therapeutics, Inc. (ACRS)vs ›	$549.58M	N/A	N/A	N/A	N/A
BlossomHill Therapeutics, Inc. (BLSM)vs ›	$549.34M	N/A	N/A	N/A	N/A
MiniMed Group, Inc. (MMEDV)vs ›	$560.00M	N/A	N/A	N/A	N/A
CorMedix Inc. (CRMD)vs ›	$566.03M	2.09x	6.25x	15.98x	15.98x
Phathom Pharmaceuticals, Inc. (PHAT)vs ›	$542.17M	N/A	N/A	N/A	N/A
Delcath Systems, Inc. (DCTH)vs ›	$539.40M	N/A	189.50x	189.50x	189.50x
CytomX Therapeutics, Inc. (CTMX)vs ›	$567.12M	N/A	14.25x	18.01x	18.01x
Aquestive Therapeutics, Inc. (AQST)vs ›	$572.76M	N/A	78.65x	78.65x	78.65x
ProKidney Corp. (PROK)vs ›	$536.22M	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBIT Ratio: N/A

NVCT EV/EBIT Ratio Metrics

NVCT Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics